HC Wainwright Brokers Lift Earnings Estimates for Immunocore

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Equities research analysts at HC Wainwright raised their Q2 2026 earnings estimates for shares of Immunocore in a report released on Thursday, May 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.25) per share for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Immunocore’s Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.20) EPS and FY2026 earnings at ($0.45) EPS.

IMCR has been the topic of several other reports. Zacks Research upgraded shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Jefferies Financial Group lowered shares of Immunocore from a “buy” rating to a “hold” rating and decreased their price target for the company from $48.00 to $33.00 in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Mizuho set a $38.00 price target on shares of Immunocore in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunocore has an average rating of “Moderate Buy” and a consensus price target of $57.75.

Immunocore Stock Down 2.5%

Immunocore stock opened at $28.85 on Tuesday. The firm has a market capitalization of $1.46 billion, a PE ratio of -52.45 and a beta of 0.74. The company’s 50-day moving average is $30.76 and its 200-day moving average is $33.26. Immunocore has a fifty-two week low of $27.44 and a fifty-two week high of $40.71. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Immunocore’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 EPS.

Insider Transactions at Immunocore

In other news, insider David M. Berman sold 5,965 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the sale, the insider owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. This represents a 50.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at approximately $399,296.05. This represents a 48.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 19,137 shares of company stock valued at $619,082. Company insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently added to or reduced their stakes in IMCR. Royal Bank of Canada increased its position in Immunocore by 45.1% in the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after acquiring an additional 13,689 shares during the period. Geode Capital Management LLC increased its position in Immunocore by 40.1% in the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company’s stock valued at $1,632,000 after acquiring an additional 14,877 shares during the period. Marshall Wace LLP increased its position in Immunocore by 425.8% in the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock valued at $4,601,000 after acquiring an additional 118,728 shares during the period. Sei Investments Co. acquired a new stake in shares of Immunocore during the second quarter worth $983,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Immunocore by 108.0% during the second quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company’s stock worth $4,480,000 after buying an additional 74,128 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.